论文部分内容阅读
IL-2/LAK 疗法是近几年发展起来的肿瘤免疫疗法,国外已将该疗法用于临床试治,取得了一定的疗效。本文综合了近两年国外试治的经验,从实用的角度介绍了LAK 细胞制备、对10多种癌症的疗效、IL-2和LAK 最适用量及最新给药方案,认为降低IL-2副作用和提高LAK 疗效是改进LAK 疗法的原则,联合应用较实用的LAK 活性增强剂(如αIFN)是LAK 疗法的前途所在,本文对LAK 疗法的前景作了展望。
IL-2/LAK therapy is a tumor immunotherapy developed in recent years. It has been used in clinical trials in foreign countries and has achieved certain efficacy. This article summarizes the experience of foreign trials in the past two years and presents a practical perspective on the preparation of LAK cells, the efficacy of more than 10 cancers, the most suitable amount of IL-2 and LAK, and the most recent dosing regimen. It is believed to reduce the side effects of IL-2. The improvement of LAK efficacy is the principle of improving LAK therapy. The application of a more practical LAK activity enhancer (such as αIFN) is the future of LAK therapy. This article looks into the future of LAK therapy.